Results of CHOP chemotherapy for diffuse large B-cell lymphoma

Brazilian Journal of Medical and Biological Research

Volumn 39, Issue 10, 2006, Pages 1315-1322

  Hallack Neto, A E ^a,b   Pereira, J ^a   Beitler, B ^a   Chamone, D A F ^a   Llacer, P D ^a   Dulley, F L ^a   Macedo, M C M A ^a   Chaoubah, A ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

CHOP lymphoma treatment; Diffuse large B cell lymphoma; ProMACE CytaBOM treatment

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; METHOTREXATE; PREDNISONE; VINCRISTINE;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; B CELL LYMPHOMA; CANCER REGRESSION; CANCER RELAPSE; CENTRAL NERVOUS SYSTEM METASTASIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DISEASE FREE SURVIVAL; DRUG MEGADOSE; FEMALE; HIGH RISK PATIENT; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROGNOSIS; UNIVERSITY HOSPITAL;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; ETOPOSIDE; FEMALE; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; METHOTREXATE; NEOPLASM STAGING; PREDNISONE; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 33847681008     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2006001000007     Document Type: Article

References (24)

1. Instituto Nacional do Câncer. Linfoma não Hodgkin. http://www.inca.gov.br. Accessed June 29, 2004.
2. Mirra AP, Latorre MRDO, Veneziano DB. Incidência de câncer no município de São Paulo, Brasil 1997-1998. Mortalidade de câncer no município de São Paulo, Brasil. Tendência no período de 1969-1998. Brasília: Ministério da Saúde; 2001.
3. Rabkin CS, Ward MH, Manns A, Blattner WA. Epidemiology of non-Hodgkin's lymphomas. In: Magrath IT (Editor), The non-Hodgkin's lymphomas. London: Arnold; 1997. p 171-186.
4. Shih LY, Liang DC. Non-Hodgkin's lymphomas in Asia. Hematol Oncol Clin North Am 1991; 5: 983-1001.
5. McKelvey EM, Gottlieb JA, Wilson HE, Haut A, Talley RW, Stephens R, et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976; 38: 1484-1493.
6. Kimby E, Brandt L, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in aggressive non-Hodgkin's lymphoma. Acta Oncol 2001; 40: 198-212.
7. Goldie JH, Coldman AJ. The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res 1984; 44: 3643-3653.
8. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002-1006.
9. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van Der LH, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-1545.
10. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
11. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971; 31: 1860-1861.
12. Magrath I. Chemotherapy in developing countries - is less better? Eur J Cancer 2003; 39: 1497-1500.
13. Fisher RI, DeVita VT Jr, Hubbard SM, Longo DL, Wesley R, Chabner BA, et al. Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy. Ann Intern Med 1983; 98: 304-309.
14. Montserrat E, Garcia-Conde J, Vinolas N, Lopez-Guillermo A, Hernandez-Nieto L, Zubizarreta A, et al. CHOP vs. ProMACE-CytaBOM in the treatment of aggressive non-Hodgkin's lymphomas: long-term results of a multicenter randomized trial. (PETHEMA: Spanish Cooperative Group for the Study of Hematological Malignancies Treatment, Spanish Society of Hematology). Eur J Haematol 1996; 57: 377-383.
15. Gordon LI, Andersen J, Colgan J, Glick J, Resnick GD, O'Connell M, et al. Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study. Cancer 1995; 75: 865-873.
16. Coltman CA, Dahlberg S, Jones SE. CHOP is curative in thirty% of patients with large cell lymphoma: a twelve-year Southwest Oncology Group follow-up. In: Skarin AT (Editor), Advances in cancer chemotherapy. New York: Park Row; 1986. p 71-78.
17. Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998; 339: 21-26.
18. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
19. Feugier P, Van HA, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23: 4117-4126.
20. Cabanillas F, Hagemeister FB, McLaughlin P, Velasquez WS, Riggs S, Fuller L, et al. Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol 1987; 5: 407-412.
21. Wilson WH, Bryant G, Bates S, Fojo A, Wittes RE, Steinberg SM, et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 1573-1582.
22. Velasques WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA, et al. ESHAP - An effective chemotherapy regimen in refractory and relapsed lymphoma: A 4-year follow-up study. J Clin Oncol 1992; 12: 1176.
23. Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M, et al. International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury. J Clin Oncol 1999; 17: 423-429.
24. Hamlin PA, Zelenetz AD, Kewalramani T, Qin J, Satagopan JM, Verbel D, et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003; 102: 1989-1996.